Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor

被引:6
|
作者
Nixon, Donald R. [1 ,2 ,3 ,4 ]
Flinn, Nicholas [1 ]
机构
[1] Trimed Eye Ctr, Barrie, ON L4M 4S5, Canada
[2] Royal Victoria Reg Hlth Ctr, Dept Surg, Barrie, ON, Canada
[3] Soldiers Mem Hosp, Dept Surg, Orillia, ON, Canada
[4] Northern Ontario Sch Med NOSM, Dept Surg, Sudbury, ON, Canada
来源
CLINICAL OPHTHALMOLOGY | 2021年 / 15卷
关键词
contrast sensitivity; residual deficit; functional impairment;
D O I
10.2147/OPTH.S304229
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: What is the level of visual function in patients with diabetic macular edema (DME) and retinal vein occlusion (RVO) post-stabilization with anti-vascular endothelial growth factor? Patients and Methods: This observational non-controlled single center study evaluated visual function in two patient populations with macular edema 25 with diabetic macular edema and 25 with retinal vein occlusion treated following standard protocol of anti-VEGF therapy post- stabilization. Results: A total of 68 eyes from 50 patients were analyzed including 18 bilateral and 7 unilateral diabetic macular edema, 14 patients with central and 11 with branch retinal vein occlusion. The mean age was 69 +/- 11 years and 64% were male. In the RVO group: LogMAR BCVA was 0.12 +/- 0.13 compared to the unaffected eye 0.04 +/- 0.05 (P=<0.01), contrast sensitivity in the treated eye was 1.69 +/- 0.21 log units compared to 1.84 +/- 0.15 log units in the unaffected eye (p=<0.01), the ganglion cell volume was 0.88 +/- 0.15 mm(3) in the treated eye compared to 1.04 +/- 0.1 mm(3) in the unaffected eye (P=<0.01). In the diabetic macular edema group: LogMAR BCVA was 0.17 +/- 0.13, contrast sensitivity in the treated eye was 1.16 +/- 0.21 log units compared to the normal population 1.92 +/- 0.8 log units (p=<0.01), the ganglion cell volume was 0.94 +/- 0.14 mm(3) in the treated eye compared to 1.03 +/- 0.12 mm(3) in the normal population (P=<0.001). In both groups a majority of treated eyes retained visual acuity >=+0.4 LogMAR (diabetic macular edema 95%, RVO 96%) however contrast sensitivity was more than two standard deviations below the normal population mean in a majority of treated eyes in both groups (diabetic macular edema 88% RVO 64%). Conclusion: Impairment in contrast sensitivity in both groups could impact activities of daily living including driving and should prompt questions about how we advise patients regarding their level of function and the potential limitations/restrictions that should be placed on such activities.
引用
收藏
页码:1659 / 1666
页数:8
相关论文
共 50 条
  • [41] Time to initiate anti-vascular endothelial growth factor therapy and visual outcome in central retinal vein occlusion
    Agata, Chisato
    Aoki, Shuichiro
    Kitamoto, Kohdai
    Azuma, Keiko
    Fujino, Ryosuke
    Inoue, Tatsuya
    Obata, Ryo
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [42] Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial
    Gurudas, Sarega
    Patrao, Namritha
    Nicholson, Luke
    Sen, Piyali
    Ramu, Jayashree
    Sivaprasad, Sobha
    Hykin, Philip
    JAMA OPHTHALMOLOGY, 2022, 140 (02) : 143 - 150
  • [43] Anti-vascular endothelial growth factor for diabetic macular oedema
    Virgili, Gianni
    Parravano, Mariacristina
    Menchini, Francesca
    Evans, Jennifer R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (10):
  • [44] Safety and Efficacy of a Treat-and-Extend Regimen of Anti-Vascular Endothelial Growth Factor Agents for Diabetic Macular Edema or Macular Edema Secondary to Retinal Vein Occlusion: A Systematic Review and Meta- Analysis
    Patil, Nikhil S.
    Dhoot, Arjan S.
    Nichani, Prem A. H.
    Popovic, Marko M.
    Muni, Rajeev H.
    Kertes, Peter J.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2023, 54 (03): : 131 - +
  • [45] CHOROIDAL BLOOD FLOW AND THICKNESS AS PREDICTORS FOR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION
    Okamoto, Masahiro
    Yamashita, Mariko
    Sakamoto, Taiji
    Ogata, Nahoko
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (03): : 550 - 558
  • [46] Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Macular Edema Associated With Central Retinal Vein Occlusion in Patients Age 40 Years or Younger
    Gao, Xinxiao
    Obeid, Anthony
    Aderman, Christopher M.
    Ali, Ferhina S.
    Vander, James F.
    Hsu, Jason
    Ho, Allen C.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2019, 50 (04): : E96 - E104
  • [47] ASSOCIATIONS WITH RECURRENCE OF MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION AFTER THE DISCONTINUATION OF ANTI VASCULAR ENDOTHELIAL GROWTH FACTOR
    Lee, Geun Woo
    Kang, Se Woong
    Kang, Min Chae
    Kim, Sang Jin
    Kim, Yoon Young
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (09): : 1892 - 1900
  • [48] Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients
    Li, Yun-Fei
    Ren, Qian
    Sun, Chao-Hui
    Li, Li
    Lian, Hai-Dong
    Sun, Rui-Xue
    Su, Xian
    Yu, Hua
    WORLD JOURNAL OF DIABETES, 2022, 13 (07) : 532 - 542
  • [49] Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema
    Jampol, Lee M.
    Glassman, Adam R.
    Liu, Danni
    Aiello, Lloyd Paul
    Bressler, Neil M.
    Duh, Elia J.
    Quaggin, Susan
    Wells, John A.
    Wykoff, Charles C.
    OPHTHALMOLOGY, 2018, 125 (07) : 1054 - 1063
  • [50] Commentary: Switching of anti-vascular endothelial growth factor agents in refractory diabetic macular edema
    Ratra, Dhanashree
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (02) : 367 - 368